Chinese Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A) Registry protocol: rationale, design and methodology
Hong Liu,Si-chong Qian,Hai-yang Li,Yong-feng Shao,Hong-jia Zhang,Lu Han,Ying-yuan Zhang,Kai Wang,Ying Wu,Liang Hong,Ji-nong Yang,Ji-sheng Zhong,Bing-qi Sun,Xiao-cheng Liu,Dong-kai Wu,Guo-liang Fan,Jun-quan Chen,Sheng-qiang Zhang,Yi-yao Jiang,Xing-xing Peng,Zhi-hua Zeng,Xin Zhao,Peng-cheng Tang,Xiao-yan Feng,Cheng-bin Tang,Hui-jun Zhang,Zhan-jie Lu,Si-qiang Zheng,Chen Zhang,Peng-cheng Zhu,Hong-hua Yue,Ling-chen Huang,Feng Wu,Xiao-han Xu,Xiao-hu Lu,Wei-dong Gu,the China Additive Anti-inflammatory Action for Aortopathy, Arteriopathy (5A) Investigators
DOI: https://doi.org/10.1186/s12872-024-03760-y
IF: 2.174
2024-02-22
BMC Cardiovascular Disorders
Abstract:Acute aortic syndrome (AAS) is a life-threatening condition. Inflammation plays a key role in the pathogenesis, development and progression of AAS, and is associated with significant mortality and morbidity. Understanding the inflammatory responses and inflammation resolutions is essential for an appropriate management of AAS.
cardiac & cardiovascular systems